…
Encompass Health Corporation operates inpatient rehabilitation hospitals in the United States and Puerto Rico. The company offers specialized rehabilitative treatment, using technology and therapy, on an inpatient basis for patients recovering from a major injury or illness and seeking to regain functional ability, independence, and quality of life; medical, nursing, therapy, and ancillary services; and rehabilitative care to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. It offers services through the Medicare program to the federal government, managed care plans and private insurers, state governments, and other patients. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was incorporated in 1984 and is based in Birmingham, Alabama.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Encompass Health operates a nationwide network of inpatient rehabilitation hospitals and home health and hospice services delivering post-acute care for patients recovering from serious illness or injury. Long-term growth may be supported by demographic aging, a shift toward home- and community-based care, and scale benefits from an integrated post-acute platform that appears positioned to capture referral flows. Investors may find the company attractive for its leading inpatient-rehab footprint and recurring, demand-driven service mix.
The most important risks are sensitivity to Medicare and commercial reimbursement changes, persistent staffing and labor-cost pressures, and execution risk tied to facility expansion and integration.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 953.00M | 749.60M | 607.20M | 450.80M | 657.20M |
| Minority interest | -192.90M | -140.90M | -107.60M | -94.90M | -105.00M |
| Net income | 566.20M | 455.70M | 352.00M | 271.00M | 412.20M |
| Selling general administrative | 236.20M | 266.50M | 201.70M | 2602.30M | 3164.00M |
| Selling and marketing expenses | - | - | 56.30M | - | - |
| Gross profit | 1289.30M | 2233.20M | 1982.80M | 4146.50M | 4912.30M |
| Reconciled depreciation | 327.90M | 299.60M | 267.10M | 243.60M | 256.60M |
| Ebit | 1076.20M | 887.00M | 731.80M | 627.90M | 822.80M |
| Ebitda | 1404.10M | 1186.60M | 1005.70M | 871.50M | 1079.40M |
| Depreciation and amortization | 327.90M | 299.60M | 273.90M | 243.60M | 256.60M |
| Non operating income net other | - | - | - | - | 15.30M |
| Operating income | 1053.10M | 864.50M | 1724.80M | 627.90M | 822.80M |
| Other operating expenses | 4882.10M | 4508.70M | 3076.40M | 3718.40M | 4315.10M |
| Interest expense | 123.20M | 137.40M | 143.50M | 175.70M | 164.60M |
| Tax provision | 192.90M | 150.20M | 126.90M | 100.10M | 139.60M |
| Interest income | 118.90M | 134.40M | 140.30M | 172.80M | 160.60M |
| Net interest income | -123.20M | -137.40M | -146.10M | -175.70M | -164.60M |
| Extraordinary items | -1.00M | -2.80M | -12.00M | 13.90M | -0.40M |
| Income tax expense | 192.90M | 150.20M | 132.20M | 100.10M | 139.60M |
| Total revenue | 5935.20M | 5373.20M | 4801.20M | 4348.60M | 5121.60M |
| Total operating expenses | 236.20M | 1368.70M | 258.00M | 3516.30M | 4105.80M |
| Cost of revenue | 4645.90M | 3140.00M | 2818.40M | 202.10M | 209.30M |
| Total other income expense net | -100.10M | -114.90M | -1117.60M | -177.10M | -165.60M |
| Discontinued operations | - | - | - | 15.20M | -0.40M |
| Net income from continuing ops | 760.10M | 599.40M | 466.40M | 350.70M | 517.60M |
| Net income applicable to common shares | 564.70M | 452.90M | 349.60M | 269.80M | 412.20M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 7089.70M | 6534.70M | 6102.40M | 5636.50M | 6864.90M |
| Intangible assets | 308.30M | 297.80M | 278.20M | 282.30M | 417.50M |
| Other current assets | 141.60M | 202.70M | 88.40M | 127.00M | 121.20M |
| Total liab | 3813.90M | 3685.50M | 3805.20M | 3774.60M | 4465.70M |
| Total stockholder equity | 2438.20M | 2067.00M | 1647.50M | 1310.30M | 1911.30M |
| Deferred long term liab | - | - | - | - | 86.70M |
| Other current liab | 588.10M | 505.10M | 437.50M | 309.20M | 219.70M |
| Common stock | 1.20M | 1.20M | 1.20M | 1.10M | 1.10M |
| Capital stock | 1.20M | 1.20M | 1.20M | 1.10M | 1.10M |
| Retained earnings | 1289.40M | 796.70M | 406.50M | 115.70M | 141.80M |
| Other liab | - | - | - | 257.20M | 259.90M |
| Good will | 1317.60M | 1284.00M | 1281.30M | 1263.20M | 2427.90M |
| Other assets | 140.10M | 219.20M | 0.00M | 222.10M | 254.50M |
| Cash | 102.90M | 85.40M | 104.20M | 21.80M | 54.80M |
| Cash and equivalents | 72.20M | 85.40M | 69.10M | 21.80M | 54.80M |
| Total current liabilities | 836.40M | 841.00M | 656.40M | 575.90M | 748.80M |
| Current deferred revenue | - | - | 42.60M | 83.00M | 310.30M |
| Net debt | 2611.00M | 2628.40M | 2828.60M | 2970.50M | 3483.40M |
| Short term debt | 70.10M | 164.90M | 48.90M | 50.80M | 81.20M |
| Short long term debt | 43.60M | 138.60M | 24.80M | 25.20M | 42.80M |
| Short long term debt total | 2713.90M | 2713.80M | 2932.80M | 2992.30M | 3538.20M |
| Other stockholder equity | 1147.10M | 1269.10M | 1239.80M | 1193.50M | 1768.40M |
| Property plant equipment | 4314.20M | 3846.80M | 3509.50M | 3151.70M | 2843.60M |
| Total current assets | 905.90M | 886.90M | 841.80M | 717.20M | 921.40M |
| Net tangible assets | - | - | - | -235.20M | -934.10M |
| Short term investments | 42.20M | 39.00M | 37.60M | - | - |
| Net receivables | 619.20M | 598.80M | 611.60M | 536.80M | 680.30M |
| Long term debt | 2447.20M | 2359.20M | 2687.80M | 2741.80M | 3243.90M |
| Inventory | - | - | 72.70M | 31.60M | 65.10M |
| Accounts payable | 178.20M | 171.00M | 170.00M | 132.90M | 137.60M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 445.70M |
| Accumulated other comprehensive income | 0.50M | - | - | - | - |
| Common stock total equity | - | - | - | - | 1.10M |
| Retained earnings total equity | - | - | - | - | 141.80M |
| Treasury stock | - | - | - | - | -521.20M |
| Non currrent assets other | 114.60M | 96.70M | 82.10M | 139.10M | 254.50M |
| Non current assets total | 6183.80M | 5647.80M | 5260.60M | 4919.30M | 5943.50M |
| Capital lease obligations | 223.10M | 216.00M | 220.20M | 225.30M | 251.50M |
| Long term debt total | 2447.20M | 2359.20M | 2687.80M | 2741.80M | 3243.90M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -653.30M | -601.10M | -627.00M | -666.30M |
| Change to liabilities | - | - | - | 2.30M | 14.90M |
| Total cashflows from investing activities | -762.80M | -653.30M | -602.80M | -627.00M | -666.30M |
| Net borrowings | -29.00M | -242.00M | -83.30M | -498.20M | -66.30M |
| Total cash from financing activities | -433.00M | -330.60M | -197.20M | -145.70M | -240.10M |
| Change to operating activities | - | - | - | -15.80M | -68.60M |
| Net income | 567.20M | 599.40M | 361.60M | 365.90M | 517.60M |
| Change in cash | -20.20M | 18.90M | 50.80M | -66.90M | -190.60M |
| Begin period cash flow | 123.10M | 104.20M | 53.40M | 120.30M | 310.90M |
| End period cash flow | 102.90M | 123.10M | 104.20M | 53.40M | 120.30M |
| Total cash from operating activities | 1175.60M | 1002.80M | 850.80M | 705.80M | 715.80M |
| Depreciation | 327.90M | 299.60M | 273.90M | 243.60M | 256.60M |
| Other cashflows from investing activities | -14.80M | -7.20M | 3.30M | -42.90M | 3.50M |
| Dividends paid | 71.10M | 62.80M | 60.40M | 99.00M | 112.40M |
| Change to account receivables | -15.20M | 3.00M | -22.40M | -16.90M | -64.30M |
| Sale purchase of stock | -158.00M | -31.10M | -8.20M | 0.00M | -6.10M |
| Other cashflows from financing activities | -174.90M | 5.30M | -45.30M | 703.30M | 203.60M |
| Change to netincome | - | - | - | 211.90M | 157.20M |
| Capital expenditures | 736.40M | 642.50M | 583.10M | 584.10M | 551.20M |
| Cash and cash equivalents changes | - | - | - | - | -190.60M |
| Change in working capital | 4.30M | 21.90M | 50.30M | -30.40M | -118.00M |
| Stock based compensation | 56.50M | 48.30M | 50.60M | 29.20M | 32.80M |
| Other non cash items | 253.90M | 22.90M | 110.50M | 69.60M | -1.00M |
| Free cash flow | 439.20M | 360.30M | 267.70M | 121.70M | 164.60M |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EHC Encompass Health Corp |
1.46 1.20% |
123.47 | 19.17 | 17.06 | 1.74 | 4.33 | 2.23 | 9.41 |
| HCA HCA Healthcare, Inc. |
12.13 2.86% |
435.61 | 14.27 | 13.46 | 1.21 | 291.34 | 1.83 | 8.99 |
| THC Tenet Healthcare Corporation |
10.17 4.08% |
259.71 | 10.08 | 12.66 | 0.96 | 4.57 | 1.43 | 5.80 |
| FSNUY Fresenius SE & Co KGaA ADR |
0.11 0.84% |
13.27 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| JDHIY JD Health International Inc |
- -% |
5.05 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
Encompass Health Corporation operates inpatient rehabilitation hospitals in the United States and Puerto Rico. The company offers specialized rehabilitative treatment, using technology and therapy, on an inpatient basis for patients recovering from a major injury or illness and seeking to regain functional ability, independence, and quality of life; medical, nursing, therapy, and ancillary services; and rehabilitative care to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. It offers services through the Medicare program to the federal government, managed care plans and private insurers, state governments, and other patients. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was incorporated in 1984 and is based in Birmingham, Alabama.
9001 Liberty Parkway, Birmingham, AL, United States, 35242
205 967 7116
24611
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark J. Tarr | CEO, Pres & Director | 1962 |
| Mr. Douglas E. Coltharp | Exec. VP & CFO | 1962 |
| Mr. John Patrick Darby | Exec. VP, Gen. Counsel & Corp. Sec. | 1965 |
| Ms. Elissa Joy Charbonneau | Chief Medical Officer | 1960 |
| Mr. Andrew L. Price | Sr. VP & Chief Accounting Officer | 1967 |
| Mr. Rusty Yeager | Chief Information Officer & Sr. VP | NA |
| Mr. Mark Miller | Sr. VP of Investor Relations & Strategic Planning | NA |
| Ms. Dawn Rock | Chief Compliance Officer | NA |
| Mr. Anthony A. Hernandez | Chief HR Officer | 1966 |
| Mr. Frank Brown | Pres of Southwest Region | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.